NRIXNurix Therapeutics, Inc.Signing up patients
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
B-cell Lymphoma · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
9Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +9.2
3 insiders sold shares within a month
Since Oct 30, 2026 · was worth 10, fading over time
Worry score9
Score over time
- Stage
- Phase 1/2
- Patients
- 150 (planned)
- Started
- Sep 30, 2026
- Main results expected
- May 2033
- Fully finished
- May 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with treatment-emergent adverse events
Measured over: Up to approximately 7 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 9.2, since 2026-10-30, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07520006 · record last updated 2026-11-03 · checked 2026-11-09 15:42 UTC